Latest filings (excl ownership)
PRE 14A
Preliminary proxy
19 Apr 24
S-8
Registration of securities for employees
1 Mar 24
10-K
2023 FY
Annual report
1 Mar 24
8-K
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
1 Mar 24
8-K
Entry into a Material Definitive Agreement
16 Feb 24
424B5
Prospectus supplement for primary offering
16 Feb 24
FWP
Free writing prospectus
14 Feb 24
424B5
Prospectus supplement for primary offering
14 Feb 24
8-K
Results of Operations and Financial Condition
14 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Other Events
5 Jan 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
EFFECT
Notice of effectiveness
14 Nov 23
CORRESP
Correspondence with SEC
9 Nov 23
UPLOAD
Letter from SEC
7 Nov 23
S-3
Shelf registration
3 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
3 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
7 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 23
8-K
Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting
17 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
DEFA14A
Additional proxy soliciting materials
11 May 23
8-K
Departure of Directors or Certain Officers
11 May 23
8-K
Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K/A
Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
10 Mar 23
S-8
Registration of securities for employees
9 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
8-K
Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
9 Mar 23
8-K
Regulation FD Disclosure
9 Jan 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Amendments to Articles of Incorporation or Bylaws
24 Oct 22
424B4
Prospectus supplement with pricing info
21 Oct 22
EFFECT
Notice of effectiveness
20 Oct 22
FWP
Free writing prospectus
19 Oct 22
S-1MEF
Registration of additional securities for an S-1
19 Oct 22
Latest ownership filings
4
Jeffrey D Marrazzo
4 Mar 24
3
Initial statement of insider ownership
29 Feb 24
SC 13G/A
GV 2019, L.P.
29 Feb 24
4
Keith Michael Gottesdiener
27 Feb 24
4
Richard Brudnick
23 Feb 24
4
Jeremy Duffield
23 Feb 24
4
ANN L. LEE
23 Feb 24
4
Meredith Goldwasser
23 Feb 24
4
Carman Alenson
23 Feb 24
SC 13D
ARCH Venture Fund XII, L.P.
22 Feb 24
4
ROBERT NELSEN
20 Feb 24
4
Change in insider ownership
20 Feb 24
4
KEITH CRANDELL
20 Feb 24
SC 13G/A
GV 2019, L.P.
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Allan Reine
19 Jan 24
3
Allan Reine
19 Jan 24
4
Keith Michael Gottesdiener
14 Nov 23
4/A
David R. Liu
26 Jul 23
4
David R. Liu
25 Jul 23
4
Change in insider ownership
22 Jun 23
144
Notice of proposed sale of securities
20 Jun 23
4
Change in insider ownership
20 Jun 23
4
Thomas Cahill
16 Jun 23
4
David P Schenkein
16 Jun 23
4
Kaye I Foster-Cheek
16 Jun 23
4
ROBERT NELSEN
16 Jun 23
4
Michael Aaron Kelly
16 Jun 23
4
Wendy Chung
16 Jun 23
4
Change in insider ownership
15 Jun 23
4
Change in insider ownership
13 Jun 23
144
Notice of proposed sale of securities
12 Jun 23
4
Change in insider ownership
9 Jun 23
4
Change in insider ownership
7 Jun 23
144
Notice of proposed sale of securities
5 Jun 23
4
Change in insider ownership
2 Jun 23
4
Change in insider ownership
31 May 23
144
Notice of proposed sale of securities
30 May 23
4
Change in insider ownership
26 May 23
4
Change in insider ownership
24 May 23